Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Follow-up of Miltenyi CAR T Therapies
NCT06508775Recruiting
- Sponsor
- Miltenyi Biomedicine GmbH
- Start
- May 2024
- Primary completion
- Dec 2040
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of zorpocabtagene autoleucel, MB-CART20.1 and zamtocabtagene autoleucel in melanoma, B-cell non-Hodgkin lymphoma, acute lymphoblastic leukemia (ALL) and 1 more, sponsored by Miltenyi Biomedicine GmbH. Primary endpoint: Adverse Events at 14 years. Started May 2024; status: recruiting.
02
Drugs
zorpocabtagene autoleucelMB-CART20.1zamtocabtagene autoleucel
03
Conditions
melanomaB-cell non-Hodgkin lymphomaacute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT06508775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06508775.